Pharmacological prevention of post-ERCP pancreatitis: Which therapy is best?

Journal of the Pancreas

Volumn 4, Issue 1, 2003, Pages 68-74

  Mariani, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Acute disease; Adrenal cortex hormones; Allopurinol; Chemicals and drugs category; Cytokines; Gabexate; Hormones; Hormones, hormone substitutes, and hormone antagonists; Hormones, synthetic; Nifedipine; Octreotide; Pancreatitis; Primary prevention; Protease inhibitors; Serine proteinase inhibitors; Somatostatin

Indexed keywords

ALLOPURINOL; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; GABEXATE; HYDROCORTISONE; METHYLPREDNISOLONE; NIFEDIPINE; OCTREOTIDE; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 10; SOMATOSTATIN; STOMACH SECRETION INHIBITOR;

ACUTE PANCREATITIS; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INCIDENCE; ODDI SPHINCTER; PATIENT SELECTION; SAMPLE SIZE; STATISTICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ECONOMICS; METHODOLOGY; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037265133     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Kozarek RA. ERCP economics. Gastrointest Endosc 1999; 49:660-2. [AN 99246313]
2. Akashi R, Kiyozumi T, Tanaka T, Sakurai K, Oda Y, Sagara K. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002; 55:50-4. [AN 21629113]
3. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003 in press.
4. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-95. [AN 22233811]
5. Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56:202-8. [AN 22140167]
6. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55:470-5. [AN 21920674]
7. Deviere J, Le Moine O, van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498-505. [AN 21100083]
8. Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33:766-72. [AN 21441562]
9. Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15:965-72. [AN 21314850]
10. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49:593-8. [AN 99246296]
11. De Palma G, Catanzano C. Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999; 94:982-5. [AN 99215652]
12. Dumot JA, Conwell DL, O'Connor JB, Ferguson DR, Vargo JJ, Barnes DS, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter placebo-controlled clinical trial. Am J Gastroenterol 1998; 93:61-5. [AN 98107865]
13. Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Gines A, Teres J. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998, 47:230-4. [AN 98199942]
14. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy - Italian Group. N Engl J Med 1996; 335:919-23. [AN 96365276]
15. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994; 26:715-8. [AN 95228572]
16. Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992; 33:1129-33. [AN 93013162]
17. Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992; 87:1561-6. [AN 93071823]
18. Guelrud M, Mendoza S, Rossiter G, Ramirez L, Barkin J. Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology 1988; 95:1050-55. [AN 88313502]
19. Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 1997; 112:960-7. [AN 97193674]
20. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-23. [AN 21122345]
21. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1-10. [AN 98347799]
22. Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low and high-osmolarity contrast agent. Gastrointest Endosc 1994; 40:422-7. [AN 95011329]
23. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18. [AN 96365275]
24. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-34. [AN 21460528]
25. Christoforidis E, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis F. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy 2002; 34:286-92. [AN 21929641]
26. Vandervoort J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56:652-6. [AN 22283811]
27. Testoni PA. Why the incidence of post-ERCP pancreatitis varies considerably? Factors affecting the diagnosis and the incidence of this complication. JOP. J Pancreas (Online) 2002; 3:195-201. [AN 22319330]
28. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7. [AN 20092786]
29. Haber GB. Prevention of post-ERCP pancreatitis. Gastrointest Endosc 2000; 51:100-3. [AN 20092814]
30. Pasha TM, Therneau T, Petersen BT. Economic analysis of gabexate mesilate in post-ERCP pancreatitis. Gastroenterology 1997; 112:471A.
31. Eandi M, Rava A, Dirindin N et al. Analisi costi-efficacia incrementale dell'uso del gabesato mesilato nella profilassi delle complicanze pancreatiche conseguenti a manovre endoscopiche sulla papilla di Vater. Farmacoeconomia 1995; 4:20
32. Lazzaro C, Fattore G. Analisi dei costi differenziali di somatostatina ed octreotide verso non trattamento nella profilassi della pancreatite acuta lieve conseguente ad ERCP. Risultati di uno studio preliminare. Giornale Italiano di Farmacia Clinica 1996; 10:9-15.
33. Bordas JM, Toledo V, Mondelo F, Rodes J. Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy. Horm Res 1988; 29:106-8. [AN 88297533]
34. Guelrud M, Mendoza S, Viera L, Gelrud D. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1991; 37:44-7. [AN 91169195]
35. Persson B, Slezak P, Efendic S, Haggmark A. Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology 1992; 39:259-61. [AN 92371924]
36. Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc 1991; 37:48-50. [AN 91169196]
37. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990; 174:331-6. [AN 90116369]
38. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383-93. [AN 91301427]
39. Ranson JH. Etiological and prognostic factors in human acute pancreatitis: a review. Am J Gastroenterol 1982; 77:633-8. [AN 82281373]